Immunosabr

27/01/2022

💡Since 2017,the ImmunoSABR clinical trial has made steady progress.

👏As of August, 8 patients have been successfully enrolled in the ImmunoSABR clinical trial across three centres in Amsterdam, Maastricht and Leuven.

👉More information here: https://www.immunosabr.org/news/

21/12/2021

😊As the holiday season is approaching, we would like to wish you all Happy Holidays and Happy New Year.

🎉We wish you a very healthy 2022!

20/12/2021

🤔Non-small cell lung cancer comprises 85% of all lung cancer cases.

👉ImmunoSABR is treating NSCLC with fewer than 10 metastases with a combination of radiotherapy and immunotherapy, testing the synergistic effects of the two therapies.

17/12/2021

👏The ImmunoSABR clinical trial has made steady progress.

👉As of August, 8 patients have been successfully enrolled in the ImmunoSABR clinical trial across three centres in Amsterdam, Maastricht and Leuven. Find out more: http://ow.ly/yyyo50HebVb

31/05/2021

🗞️🗞️🗞️Do not miss the latest news from ImmunoSABR project! https://bit.ly/3i627SD

Information about and for partners, publications, patients enrolled on the Clinical Trial and much more. Check it out😊

07/04/2021

In which way is the ImmunoSABR project disruptive?🤔 How will immunotherapy change radiotherapy?

🗣️The main investigator of the project, Prof Philippe Lambin has all answers for you. Take a look at the video interview:

31/03/2021

🙋‍♂️🙋‍♀️Patients needed! We are looking for patients willing to participate in the next step of the project: a multicentric randomized phase 2 clinical trial in lung cancer patients.

Watch this video and check our website to learn more:

24/03/2021

Prof. Lambin, PhD in molecular biology, is the main investigator of the project🔬 Would you like to know first-hand what is the project about? Check this video!

17/03/2021

The ImmunoSABR trial team has developed an app for potential participants. The next step is a multicentric randomized phase 2 clinical trial in lung cancer patients.

Find the latest updates here➡️ bit.ly/3lwKY4b

ImmunoSABR is a six-year research project funded by the European Commission's Horizon 2020: the EU Framework for Programme for Research and Innovation. It is...

04/03/2021

On six occasions, Susan went through a three-week cycle and she suffered several side effects. When she finished the course, the side effects stopped immediately.

Susan was one of the patients treated successfully with L19-IL2. Do you want to read her story? Check it out➡️ https://bit.ly/3agByGw

01/03/2021

The ImmunoSABR trial results of Susan Smith were exceptional because there was very little chance that she could have achieved these results with the regular form of treatment. Do you want to read her patient testimonial? https://bit.ly/3agByGw

ImmunoSABR project aims at studying whether immunotherapy after a standard treatment such as radiotherapy, is more effective than the standard treatment👩🏻‍🔬👨🏻‍🔬

25/02/2021

The persistent cough of Susan Smith (57) was found to be a symptom of advanced lung cancer. She quickly began the first rounds of chemotherapy, in combination with radiotherapy. Soon after, her doctor suggested her to participate in the clinical study of ImmunoSABR.

Results in patients like Susan are motivating to study this new treatment further 🧐 Would you like to know more? https://bit.ly/3agByGw